Hi,
moomoo ID:NaN
Log Out
English
Back
Log in to access Online Inquiry
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data
ARVN Arvinas
41.390
+1.640+4.13%
Post Mkt Price
41.3900.0000.00%
YOY
Do not show
Hide blank lines
(Q3)2022/09/30(Q2)2022/06/30(Q1)2022/03/31(FY)2021/12/31
Total revenue
226.34% 30.3M 464.53% 31.3M 336.87% 24.2M 114.20% 46.7M
Operating revenue
226.34% 30.3M 464.53% 31.3M 336.87% 24.2M 114.20% 46.7M
Cost of revenue
Gross profit
Operating expense
72.21% 97.5M 73.45% 99.6M 78.44% 84.2M 65.01% 242M
Selling and administrative expenses
24.90% 20M 68.62% 24.3M 63.98% 20.2M 60.82% 61.6M
-General and administrative expense
24.90% 20M 68.62% 24.3M 63.98% 20.2M 60.82% 61.6M
Research and development costs
90.87% 77.5M 75.07% 75.3M 83.56% 64M 66.49% 180.4M
Operating profit
-41.98% -67.2M -31.66% -68.3M -44.07% -60M -56.42% -195.3M
Net non-operating interest income expense
843.34% 3.4M 411.31% 1.8M 176.41% 1.2M -48.88% 1.8M
Non-operating interest income
822.55% 3.4M 399.78% 1.8M 166.44% 1.2M -47.01% 1.9M
Non-operating interest expense
-- -- -- -- -- -- 53.85% 100K
Other net income (expense)
-191.30% -200K -108.09% -100K -140.35% -100K 24.72% 2.5M
Earnings from equity interest
-- -- -- -- -- -- -- 0
Other non- operating income (expenses)
-191.30% -200K -108.09% -100K -140.35% -100K 24.72% 2.5M
Income before tax
-36.89% -64M -32.44% -66.6M -43.78% -58.9M -60.06% -191M
Income tax
2.2M 3.4M 4.5M
Net income
-41.60% -66.2M -39.20% -70M -54.77% -63.4M -60.06% -191M
Net income continuous Operations
-41.60% -66.2M -39.20% -70M -54.77% -63.4M -60.06% -191M
Minority interest income
Net income attributable to the parent company
-41.60% -66.2M -39.20% -70M -54.77% -63.4M -60.06% -191M
Preferred stock dividends
Other preferred stock dividends
Net income attributable to common stockholders
-41.60% -66.2M -39.20% -70M -54.77% -63.4M -60.06% -191M
Basic earnings per share
-31.91% -1.24 -28.16% -1.32 -42.86% -1.2 -26.49% -3.82
Diluted earnings per share
-31.91% -1.24 -28.16% -1.32 -42.86% -1.2 -26.49% -3.82
Dividend per share
Currency Unit
USDUSDUSDUSD
Accounting Standards
US-GAAPUS-GAAPUS-GAAPUS-GAAP
Audit Opinions
------Unqualified Opinion

FY: Financial Year Annual Report, which is equivalent to the 10-K file disclosed by the listed company to the SEC.

Q: Quarterly report, which is equivalent to the 10-Q file disclosed by the listed company to the SEC, where Q1, Q2, Q3, and Q4 are single quarterly reports with a span of 3 months; Q6 and Q9 are cumulative quarterly reports, and Q6 is 6 months , Q9 is 9 months.

The MOM data from the Quarterly report,MOM=(current period - last period)/last period *100%

Company Overview More
Arvinas, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its product candidates are ARV-110, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer, ARV-471, and ARV-766, a PROTAC protein degrader targeting the estrogen receptor protein for the treatment of patients with metastatic ER positive/HER2 negative breast cancer. The company was founded in February 2013 and is headquartered in New Haven, CT.
CEO: Dr. John G. Houston, PhD
Market: NASDAQ
Listing Date: 09/27/2018
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...

Watchlist